Clinical trial NCT00427219: The Safety and Efficacy of Ozarelix to Treat Men With Lower Urinary Tract Symptoms Due to Enlargement of the Prostate
Official title: A Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of Ozarelix, in Patients With Lower Urinary Tract Symptoms(LUTS) Due to Benign Prostatic Hypertrophy (BPH)
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE2
Conditions: Benign Prostatic Hypertrophy
Keywords: Benign Prostatic Hyperplasia
Prostatic Adenoma, Benign
Prostatic Hypertrophy, Benign
Enlarged Prostate
Prostatism
Adenoma, Prostatic
Lead sponsor: Spectrum Pharmaceuticals, Inc
Sponsor class: INDUSTRY
First posted: 2007-01-26
Enrollment: 74
Sex: MALE
Minimum age (years): 50
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study is to compare the efficacy and safety of ozarelix 15 mg given intramuscular (IM) 2 weeks apart on the improvement of symptoms and the duration of improvement for up to 6 months in men with Benign Prostatic Hypertrophy (BPH) who are over 50 years of age.

Detailed description: This study is to compare the improvement in symptom scores, peak flow rate and quality of life in men suffering from lower urinary tract symptoms (LUTS) secondary to Benign Prostatic Hypertrophy (BPH) following treatment with ozarelix. Ozarelix is compared to placebo and injections given 14 days apart. Patients are followed for 6 months and both safety and efficacy assessed at monthly visits. Additionally, the impact of treatment on erectile function, if any, as well as Prostate-Specific Antigen (PSA) and Testosterone levels will be monitored.

The screening period of 7 days. The duration of the study is 40 weeks, including a 28-day placebo run-in phase (eligible participants entered a placebo run-in phase in which placebo is administered twice over a 2 week period \[Day -28 and Day -14\] and participants are assessed to establish baseline values approximately 14 days following the second placebo injection), study drug is administered on Days 0 and 14 followed by 34 weeks of observation after the last dose of study drug.

Eligibility criteria: Inclusion Criteria:

- All of the following questions must be answered "Yes" at Visit 1 in order for the participant to participate in the study.

* Is the participant at least 50 years old?
* Does the participant have clinical signs and symptoms consistent with BPH?
* Does the participant have an IPSS 13 at screening (prior to placebo run in)?
* Does the participant have a peak urinary flow rate (Qmax) of 4-15 milliliter/second (mL/sec) established on a voided volume of at least 125 mL?
* Is the participant willing to agree not to use any other approved or experimental pharmacologic BPH treatments including alpha blockers, 5-alpha reductase inhibitors, anti-cholinergic preparations or herbal preparations at any time during the study?

Exclusion Criteria: All of the following questions must be answered "No" at Visit 1 in order for the participant to participate in the study.

* Does the participant have a history of prostate cancer or a serum PSA \>10 nanograms per milliliter (ng/mL)?
* Has the participant had prior prostate or bladder surgery, pelvic surgery (excluding hernia repair), pelvic radiation or lower urinary tract malignancy?
* Does the participant have a prevoid total bladder volume assessed by ultrasound \> 550 mL?
* Does the participant have a residual urine volume \> 350 mL by ultrasound?

Primary outcomes:
measure: Change From Baseline in International Prostate Symptom Score (IPSS)
timeFrame: 12 weeks
Secondary outcomes:
measure: International Prostate Symptom Score - Quality of Life (IPSS-QOL)
timeFrame: 36 weeks
measure: BPH Impact Index (BPHII)
timeFrame: 36 weeks
measure: Lower Urinary Tract Symptoms (LUTS) Global Assessment Question (LUTS-GAQ)
timeFrame: 36 weeks
measure: International Index of Erectile Function-15 (IIEF-15)
timeFrame: 36 weeks
measure: Maximum Urinary Flow Rate (Qmax)
timeFrame: 36 weeks
measure: Number of Participants With Adverse Events
timeFrame: 36 weeks
Other outcomes:
Locations:
city: Tucson
country: United States
facility: Donald Gleason, MD
state: Arizona
city: Laguna Hills
country: United States
facility: Jay Young, MD
state: California
city: Los Angeles
country: United States
facility: Alexander Gershman, MD
state: California
city: Newport Beach
country: United States
facility: Stephen Auerbach, MD
state: California
city: Tarzana
country: United States
facility: Eugene Dula, MD
state: California
city: Aurora
country: United States
facility: Joel Kaufman, MD
state: Colorado
city: Ocala
country: United States
facility: Ira Klimberg, MD
state: Florida
city: Meridian
country: United States
facility: Joseph Williams, MD
state: Idaho
city: Fort Wayne
country: United States
facility: Christopher Steidle, MD
state: Indiana
city: Saint Louis
country: United States
facility: Steven Bigg, MD
state: Missouri
city: New York
country: United States
facility: Jed Kaminetsky, MD
state: New York
city: San Antonio
country: United States
facility: William Fitch, MD
state: Texas
city: Virginia Beach
country: United States
facility: Gregg Eure, MD
state: Virginia
Study officials:
References: